ribonuclease/neoplasms

BACKGROUND OF THE INVENTION The development of new drugs has contributed to the progress that has been made in recent years in the treatment of various types of cancer. However, certain cancers are refractory to the chemotherapeutic agents that are currently in use. These malignancies tend to be

FIELD OF THE INVENTION The present invention relates generally to conjugates of ribonucleases (e.g., human ribonucleases) and water-soluble polymers, compositions comprising the conjugates and methods of using the same. In particular, the present invention provides conjugates of ribonucleases (e.g.,

CROSS-REFERENCE TO RELATED APPLICATIONS This application is an U.S. national stage of PCT/CN2012/081166, filed on Sep. 10, 2012, which claims priority to Chinese Patent Application No. 201110280177.8, filed on Sep. 20, 2011 and Chinese Patent Application No. 201110280179.7, filed on Sep. 20, 2011,

FIELD OF THE INVENTION The present invention relates generally to conjugates of ribonucleases (e.g., RNase 1 and RNase A) and water-soluble polymers, compositions comprising the conjugates and methods of using the same. In particular, the present invention provides conjugates of ribonucleases and

FIELD OF THE INVENTION The present invention relates to an antitumor or antineoplastic agent and a tumor cell metastasis suppressive agent (hereinafter "antimetastatic agent"). Stated more specifically, it relates to an antitumor agent having a ribonuclease inhibitor as an active component, and more

FIELD OF THE INVENTION The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target

FIELD OF THE INVENTION The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target

FIELD OF THE INVENTION The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target

FIELD OF THE INVENTION The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells. BACKGROUND OF THE INVENTION The term "chemotherapy"

FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT Not applicable. BACKGROUND OF THE INVENTION Ribonucleases such as ribonuclease A ("RNase A") and their cytotoxicity towards tumor cells were discovered in the 1960s (reviewed in Roth, J., Cancer Res. 23:657 666 (1963)). In the 1970s, human serum was also

BACKGROUND OF INVENTION For the maintenance, and also for the division of cells, it is necessary for the cell to reproduce its genome (DNA), then to transcribe the genes (DNA) into various RNAs among which are messenger RNAs, which in turn direct the synthesis of proteins. The biological medium that

BACKGROUND OF THE INVENTION Toxic enzymes from plants and bacteria such as ricin, diphtheria toxin and Pseudomonas toxin have been coupled to antibodies or receptor binding ligands to generate cell-type-specific-killing reagents (Youle, et al., Proc. Nat'l Acad. Sci. USA 77:5483 (1980); Gilliland,

CROSS-REFERENCE TO RELATED APPLICATIONS The present application is related to U.S. patent application Ser. No. 12/157,985, entitled METHODS FOR COLLECTING AND DETECTING OLIGONUCLEOTIDES, naming Paul G. Allen, Edward S. Boyden, Roderick A. Hyde, Muriel Y. Ishikawa, Stephen L. Malaska, Dennis J.

SUMMARY The method described herein comprises accurately sampling a RNA from a tissue of an animal and analyzing RNA in the tissue of the animal as an indicator of physiological state, infectious disease, neoplastic disease, autoimmune disease, inflammatory disease, cardiovascular disease, or

CROSS-REFERENCE TO RELATED APPLICATIONS The present application is related to U.S. patent application Ser. No. 12/157,984, entitled METHODS, COMPOSITIONS, AND KITS FOR COLLECTING AND DETECTING OLIGONUCLEOTIDES, naming Paul G. Allen, Edward S. Boyden, Roderick A. Hyde, Muriel Y. Ishikawa, Stephen L.